腹部念珠菌病是棘白菌素耐药性的一个隐匿来源。
Abdominal candidiasis is a hidden reservoir of echinocandin resistance.
作者信息
Shields Ryan K, Nguyen M Hong, Press Ellen G, Clancy Cornelius J
机构信息
Department of Medicine, University of Pittsburgh, Pittsburgh, Pennsylvania, USA XDR Pathogen Laboratory, University of Pittsburgh Medical Center, Pittsburgh, Pennsylvania, USA.
Department of Medicine, University of Pittsburgh, Pittsburgh, Pennsylvania, USA XDR Pathogen Laboratory, University of Pittsburgh Medical Center, Pittsburgh, Pennsylvania, USA
出版信息
Antimicrob Agents Chemother. 2014 Dec;58(12):7601-5. doi: 10.1128/AAC.04134-14. Epub 2014 Oct 6.
Abstract
FKS mutant Candida isolates were recovered from 24% (6/25) of abdominal candidiasis patients exposed to echinocandin. Candida glabrata (29%) and Candida albicans (14%) mutants were identified. Multidrug-resistant bacteria were recovered from 83% of FKS mutant infections. Mutations were associated with prolonged echinocandin exposure (P = 0.01), breakthrough infections (P = 0.03), and therapeutic failures despite source control interventions (100%). Abdominal candidiasis is a hidden reservoir for the emergence of echinocandin-resistant Candida.
摘要
从24%（6/25）接受棘白菌素治疗的腹部念珠菌病患者中分离出FKS突变型念珠菌菌株。鉴定出光滑念珠菌（29%）和白色念珠菌（14%）突变体。83%的FKS突变体感染中分离出多重耐药菌。突变与棘白菌素暴露时间延长（P = 0.01）、突破性感染（P = 0.03）以及尽管采取了源头控制干预措施仍出现治疗失败（100%）相关。腹部念珠菌病是棘白菌素耐药念珠菌出现的一个隐匿来源。
相似文献
1
Abdominal candidiasis is a hidden reservoir of echinocandin resistance.
Antimicrob Agents Chemother. 2014 Dec;58(12):7601-5. doi: 10.1128/AAC.04134-14. Epub 2014 Oct 6.
2
Increasing echinocandin resistance in Candida glabrata: clinical failure correlates with presence of FKS mutations and elevated minimum inhibitory concentrations.
Clin Infect Dis. 2013 Jun;56(12):1724-32. doi: 10.1093/cid/cit136. Epub 2013 Mar 13.
3
FKS mutant Candida glabrata: risk factors and outcomes in patients with candidemia.
Clin Infect Dis. 2014 Sep 15;59(6):819-25. doi: 10.1093/cid/ciu407. Epub 2014 May 30.
4
The presence of an FKS mutation rather than MIC is an independent risk factor for failure of echinocandin therapy among patients with invasive candidiasis due to Candida glabrata.
Antimicrob Agents Chemother. 2012 Sep;56(9):4862-9. doi: 10.1128/AAC.00027-12. Epub 2012 Jul 2.
5
Accuracy of Sensititre YeastOne echinocandins epidemiological cut-off values for identification of FKS mutant Candida albicans and Candida glabrata: a ten year national survey of the Fungal Infection Network of Switzerland (FUNGINOS).
Clin Microbiol Infect. 2018 Nov;24(11):1214.e1-1214.e4. doi: 10.1016/j.cmi.2018.05.012. Epub 2018 Jun 15.
6
Emerging echinocandin-resistant Candida albicans and glabrata in Switzerland.
Infection. 2020 Oct;48(5):761-766. doi: 10.1007/s15010-020-01475-8. Epub 2020 Jul 13.
7
Mechanisms of echinocandin antifungal drug resistance.
Ann N Y Acad Sci. 2015 Sep;1354(1):1-11. doi: 10.1111/nyas.12831. Epub 2015 Jul 17.
8
The Gastrointestinal Tract Is a Major Source of Echinocandin Drug Resistance in a Murine Model of Candida glabrata Colonization and Systemic Dissemination.
Antimicrob Agents Chemother. 2017 Nov 22;61(12). doi: 10.1128/AAC.01412-17. Print 2017 Dec.
9
FKS2 mutations associated with decreased echinocandin susceptibility of Candida glabrata following anidulafungin therapy.
Antimicrob Agents Chemother. 2011 Mar;55(3):1312-4. doi: 10.1128/AAC.00589-10. Epub 2010 Dec 13.
10
Rate of FKS Mutations among Consecutive Candida Isolates Causing Bloodstream Infection.
Antimicrob Agents Chemother. 2015 Dec;59(12):7465-70. doi: 10.1128/AAC.01973-15. Epub 2015 Sep 21.
引用本文的文献
1
Beyond Conventional Antifungals: Combating Resistance Through Novel Therapeutic Pathways.
Pharmaceuticals (Basel). 2025 Mar 4;18(3):364. doi: 10.3390/ph18030364.
2
Mechanisms of multidrug resistance caused by an Ipi1 mutation in the fungal pathogen Candida glabrata.
Nat Commun. 2025 Jan 25;16(1):1023. doi: 10.1038/s41467-025-56269-z.
3
A Narrative Review of Invasive Candidiasis in the Intensive Care Unit.
Ther Adv Pulm Crit Care Med. 2024 Dec 12;19:29768675241304684. doi: 10.1177/29768675241304684. eCollection 2024 Jan-Dec.
4
In Vivo Efficacy of Rezafungin, Anidulafungin, Caspofungin, and Micafungin against Four Clades in a Neutropenic Mouse Bloodstream Infection Model.
J Fungi (Basel). 2024 Aug 29;10(9):617. doi: 10.3390/jof10090617.
5
Evolutionary dynamics in gut-colonizing Candida glabrata during caspofungin therapy: Emergence of clinically important mutations in sphingolipid biosynthesis.
PLoS Pathog. 2024 Sep 9;20(9):e1012521. doi: 10.1371/journal.ppat.1012521. eCollection 2024 Sep.
6
Management of intra-abdominal infections: recommendations by the Italian council for the optimization of antimicrobial use.
World J Emerg Surg. 2024 Jun 8;19(1):23. doi: 10.1186/s13017-024-00551-w.
7
Intra-abdominal infections survival guide: a position statement by the Global Alliance For Infections In Surgery.
World J Emerg Surg. 2024 Jun 8;19(1):22. doi: 10.1186/s13017-024-00552-9.
8
Pharmacokinetic and pharmacodynamic considerations for antifungal therapy optimisation in the treatment of intra-abdominal candidiasis.
Crit Care. 2023 Nov 20;27(1):449. doi: 10.1186/s13054-023-04742-w.
9
Critical appraisal beyond clinical guidelines for intraabdominal candidiasis.
Crit Care. 2023 Oct 3;27(1):382. doi: 10.1186/s13054-023-04673-6.
10
The Role of Novel Antifungals in the Management of Candidiasis: A Clinical Perspective.
Mycopathologia. 2023 Dec;188(6):937-948. doi: 10.1007/s11046-023-00759-5. Epub 2023 Jul 20.
本文引用的文献
1
FKS mutant Candida glabrata: risk factors and outcomes in patients with candidemia.
Clin Infect Dis. 2014 Sep 15;59(6):819-25. doi: 10.1093/cid/ciu407. Epub 2014 May 30.
2
Undiagnosed invasive candidiasis: incorporating non-culture diagnostics into rational prophylactic and preemptive antifungal strategies.
Expert Rev Anti Infect Ther. 2014 Jul;12(7):731-4. doi: 10.1586/14787210.2014.919853. Epub 2014 May 21.
3
Candida glabrata intra-abdominal candidiasis is characterized by persistence within the peritoneal cavity and abscesses.
Infect Immun. 2014 Jul;82(7):3015-22. doi: 10.1128/IAI.00062-14. Epub 2014 May 5.
4
Real-world experience with echinocandin MICs against Candida species in a multicenter study of hospitals that routinely perform susceptibility testing of bloodstream isolates.
Antimicrob Agents Chemother. 2014;58(4):1897-906. doi: 10.1128/AAC.02163-13. Epub 2014 Jan 6.
5
Anidulafungin and micafungin MIC breakpoints are superior to that of caspofungin for identifying FKS mutant Candida glabrata strains and Echinocandin resistance.
Antimicrob Agents Chemother. 2013 Dec;57(12):6361-5. doi: 10.1128/AAC.01451-13. Epub 2013 Sep 23.
6
Interlaboratory variability of Caspofungin MICs for Candida spp. Using CLSI and EUCAST methods: should the clinical laboratory be testing this agent?
Antimicrob Agents Chemother. 2013 Dec;57(12):5836-42. doi: 10.1128/AAC.01519-13. Epub 2013 Sep 9.
7
Caspofungin MICs correlate with treatment outcomes among patients with Candida glabrata invasive candidiasis and prior echinocandin exposure.
Antimicrob Agents Chemother. 2013 Aug;57(8):3528-35. doi: 10.1128/AAC.00136-13. Epub 2013 May 13.
8
Increasing echinocandin resistance in Candida glabrata: clinical failure correlates with presence of FKS mutations and elevated minimum inhibitory concentrations.
Clin Infect Dis. 2013 Jun;56(12):1724-32. doi: 10.1093/cid/cit136. Epub 2013 Mar 13.
9
The presence of an FKS mutation rather than MIC is an independent risk factor for failure of echinocandin therapy among patients with invasive candidiasis due to Candida glabrata.
Antimicrob Agents Chemother. 2012 Sep;56(9):4862-9. doi: 10.1128/AAC.00027-12. Epub 2012 Jul 2.
10
Impact of treatment strategy on outcomes in patients with candidemia and other forms of invasive candidiasis: a patient-level quantitative review of randomized trials.
Clin Infect Dis. 2012 Apr;54(8):1110-22. doi: 10.1093/cid/cis021. Epub 2012 Mar 12.
Zotero 插件